🚀 VC round data is live in beta, check it out!
YungShin Global Holding Valuation Multiples
Discover revenue and EBITDA valuation multiples for YungShin Global Holding and similar public comparables like SIGA Technologies, NervGen Pharma, Knight Therapeutics, TaiMed Biologics and more.
YungShin Global Holding Overview
About YungShin Global Holding
YungShin Global Holding Co Ltd invests, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicine, and cosmetics. The company derives revenue from the sale of Human drugs, Health food, Animal drugs, and Others. The company generates the majority of its revenue from Human drugs. Geographically, the company generates the revenue from Taiwan, the USA, Japan, and China, out of which the majority of its revenue is generated from Taiwan.
Founded
2011
HQ
Employees
20
Website
Sectors
Financials (FY)
EV
$435M
YungShin Global Holding Financials
YungShin Global Holding reported last fiscal year revenue of $252M and EBITDA of $61M.
In the same fiscal year, YungShin Global Holding generated $110M in gross profit, $61M in EBITDA, and $37M in net income.
YungShin Global Holding P&L
In the most recent fiscal year, YungShin Global Holding reported revenue of $252M and EBITDA of $61M.
YungShin Global Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $252M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $110M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 44% | XXX | XXX | XXX |
| EBITDA | — | XXX | $61M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 24% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 16% | XXX | XXX | XXX |
| Net Profit | — | XXX | $37M | XXX | XXX | XXX |
| Net Margin | — | XXX | 15% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
YungShin Global Holding Stock Performance
YungShin Global Holding has current market cap of $463M, and enterprise value of $435M.
Market Cap Evolution
YungShin Global Holding's stock price is $1.74.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $435M | $463M | (0.9%) | XXX | XXX | XXX | $0.14 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialYungShin Global Holding Valuation Multiples
YungShin Global Holding trades at 1.7x EV/Revenue multiple, and 7.1x EV/EBITDA.
YungShin Global Holding Financial Valuation Multiples
As of March 7, 2026, YungShin Global Holding has market cap of $463M and EV of $435M.
Equity research analysts estimate YungShin Global Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
YungShin Global Holding has a P/E ratio of 12.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $463M | XXX | $463M | XXX | XXX | XXX |
| EV (current) | $435M | XXX | $435M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 7.1x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 10.8x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.9x | XXX | XXX | XXX |
| P/E | — | XXX | 12.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 12.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified YungShin Global Holding Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
YungShin Global Holding Margins & Growth Rates
YungShin Global Holding's revenue in the last fiscal year grew by 14%.
YungShin Global Holding Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 33% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 16% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
YungShin Global Holding Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SIGA Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| NervGen Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Knight Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| TaiMed Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Formycon | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
YungShin Global Holding M&A Activity
YungShin Global Holding acquired XXX companies to date.
Last acquisition by YungShin Global Holding was on XXXXXXXX, XXXXX. YungShin Global Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by YungShin Global Holding
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialYungShin Global Holding Investment Activity
YungShin Global Holding invested in XXX companies to date.
YungShin Global Holding made its latest investment on XXXXXXXX, XXXXX. YungShin Global Holding invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by YungShin Global Holding
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout YungShin Global Holding
| When was YungShin Global Holding founded? | YungShin Global Holding was founded in 2011. |
| Where is YungShin Global Holding headquartered? | YungShin Global Holding is headquartered in Taiwan. |
| How many employees does YungShin Global Holding have? | As of today, YungShin Global Holding has over 20 employees. |
| Is YungShin Global Holding publicly listed? | Yes, YungShin Global Holding is a public company listed on Taiwan Stock Exchange. |
| What is the stock symbol of YungShin Global Holding? | YungShin Global Holding trades under 3705 ticker. |
| When did YungShin Global Holding go public? | YungShin Global Holding went public in 2011. |
| Who are competitors of YungShin Global Holding? | YungShin Global Holding main competitors are SIGA Technologies, NervGen Pharma, Knight Therapeutics, TaiMed Biologics. |
| What is the current market cap of YungShin Global Holding? | YungShin Global Holding's current market cap is $463M. |
| What is the current revenue of YungShin Global Holding? | YungShin Global Holding's last fiscal year revenue is $252M. |
| What is the current EV/Revenue multiple of YungShin Global Holding? | Current revenue multiple of YungShin Global Holding is 1.7x. |
| Is YungShin Global Holding profitable? | No, YungShin Global Holding is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.